Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban adjunctive therapy for idiopathic sudden sensorineural hearing loss
IRCT20200708048051N1Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic sudden sensorineural hearing loss (ISSNHL) comparing Standard treatment + rivaroxaban with Standard treatment + placebo (2 arms). Primary endpoint: Pure tone audiometry at 3 months. Started Aug 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on IRCT20200708048051N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200708048051N1.